ArticleResearch and reports in urology2025
As a New Tumor Suppressor Gene, PID1 Activates the AMPK-mTOR Signal to Inhibit the Progression of Bladder Cancer.
Article in Research and reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bladder cancer is one of the ten most common cancers in the world, with a high incidence rate and mortality, and therefore a major burden on the global health care system. PID1 (Phosphotyrosine Interaction Domain 1) functions as an intracellular receptor protein for LRP1. The purpose of this study was to explore the role of PID1 in bladder cancer. Methods: RNA-seq data analysis was conducted on 404 BLCA specimens and 28 normal specimens to identify differentially expressed genes. The findings indicated a strong correlation between PID1 expression levels and bladder cancer. We constructed a bladder cancer cell line stably overexpressing PID1 and assessed its impact on cell proliferation and migration. Additionally, We used RT-112 cells to induce tumor formation in nude mice to study the function of the Results: PID1 expression was notably low in bladder cancer tissues. Compared to SV-HUC-1, RT-112, and SCaBER bladder cells exhibited significantly reduced PID1 expression. Overexpressing PID1 in cells led to the promotion of apoptosis in bladder cancer cells and suppressed cell proliferation and metastasis. In vivo, the overexpression of PID1 demonstrated a significant inhibitory effect on bladder cancer. Furthermore, it was capable of activating the AMPK-mTOR signaling pathway, thereby inhibiting tumor progression. Conclusion: PID1 exhibits a potent inhibitory effect on bladder cancer and activates the AMPK-mTOR signaling pathway to hinder tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.